Navigation Links
Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
Date:12/20/2007

pproximately 16 percent ownership in Ceregene. In addition, Cell Genesys has outlicensed various non-core technologies including other gene delivery technology and gene activation technology resulting in over $60 million in non-dilutive financing.

"We are pleased to initiate the intellectual property portfolio of GBP IP with this premiere set of lentiviral vector intellectual property assets from Cell Genesys," commented GBP Capital's managing partner, Dr. Douglas Lind. "Cell Genesys has been at the forefront of lentiviral vector technology development. This technology shows great promise to impact the fields of vaccine manufacturing, protein production, cell and gene therapy, and RNA interference."

Management of the portfolio, including patent prosecution and license management, has been assigned to Lentigen Corporation. Dr. Lind further added, "Lentigen's technical prominence in the field and its collaborative business strategy make it well suited to rapidly leverage the value of the Cell Genesys portfolio." Parties with interest in further information may contact Dr. Greg Feulner at Lentigen as noted below.

"We are delighted that Lentigen will be able to develop and commercialize Cell Genesys' lentiviral vector IP estate," commented Lentigen's Founder and CEO Dr. Boro Dropulic. "Lentiviral vector technology has enormous potential as research and drug discovery tools, a manufacturing platform for biologics, and for the development of novel genetic therapies. We intend to develop this technology in each of these areas in collaboration with our existing and future partners." Dr. Dropulic further added, "With this acquisition GBP Capital continues to demonstrate remarkable vision and commitment to the future of cell and gene therapy."

About Lentiviral Vectors

Lentiviral vectors are modified viruses that are used to transfer a therapeutic gene into a target cell, either ex vivo or in vivo. In preclinical studies, lentivirus vectors d
'/>"/>

SOURCE Cell Genesys, Inc.; GBP IP, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 ... valued at $5.6 billion in 2019. It is ... from 2013 to 2019, and was valued at ... report published by Transparency Market Research. , For ... visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, ...
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... GlaxoSmithKline Will Also Be Vying to Capture, Shares of ... ... from Decision Resources, WALTHAM, Mass., Nov. 19 Decision ... pharmaceutical and,healthcare issues, finds that the most promising antibiotics in ...
... 18 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS, Nasdaq: PXSL) today ... Purchase Plan which closed on 9 November 2007. ... purchase up to $5,000 worth of,shares each at ... the,recent placement. A total of 2,496 shareholders ...
... BERKELEY HEIGHTS, N.J., Nov. 16 Genta,Incorporated (Nasdaq: ... letter from the NASDAQ Stock Market stating that the,Company,s ... Global,Market because the Company does not comply with the ... as set forth in,Marketplace Rule 4450(a)(3). The Company intends ...
Cached Biology Technology:Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline 2Pharmaxis Closes Share Purchase Plan 2Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market 2Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market 3
(Date:8/29/2014)... number of connections in transcription factor networks (TFNs) to ... study published in PLOS Computational Biology in ... contributes to a network,s resilience against mutations. , ... of TFN models has a greater effect on robustness ... assortativity," said Dov A. Pechenick, PhD, lead author and ...
(Date:8/29/2014)... of marine phytoplankton, such as the prolific bloomer ... (thiamine), researchers have discovered. The finding contradicts the common ... eukaryotic microbes depend on scarce supplies of thiamine in ... way to think about the ocean," says CIFAR Senior ... ISME Journal paper with CIFAR fellows John ...
(Date:8/29/2014)... Tibetan plateau -- the largest topographic anomaly above sea ... profound effect on climate and its reflection of continental ... , Katharine Huntington and colleagues employ a cutting-edge geochemical ... fossil snail shells to investigate the uplift history of ... range widely on the timing of surface uplift of ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... eye, and intestinal tract infections, and, like other viruses, ... order to produce proteins and their own viral spawn. ... from Chinese and Australian universities has found a way ... damage the viruses in the laboratory environment, before they ...
... -- Parkinson,s disease is marked by the abnormal accumulation ... in the substantia nigra region of the brain. A ... NACP-Rep1 has been implicated as a risk factor for ... variants of NACP-Rep1 and its interaction with the microtubule-associated ...
... having an effect on Earth,s ecosystems but it,s not just ... we are causing. Now you can add an over-abundance of ... question is how large of an impact will be felt. ... Science (Dec. 16, 2011), Arizona State University researcher ...
Cached Biology News:Plasma treatment zaps viruses before they can attack cells 2Genetic factors can predict the progression of Parkinson's disease 2Researchers assess effects of a world awash in nitrogen 2
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... and highly photostable FluoSpheres microspheres have ... variety of applications requiring probes that ... protein- and other macromolecule-labeled microspheres have ... to bind to non-target surfaces in ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Biology Products: